Inventor · disambiguated record
Laurence Zitvogel
Also filed as: ZITVOGEL LAURENCE
22 granted patents·12 pending applications·156 citations·filing 1999–2025
94Inventor score
Top patents by PatentIndex Score
34 records- 0189US10765710B2Combination of oncolytic virus with immune checkpoint modulatorsROUSSY INST GUSTAVE·Filed 2015·Granted Sep 8, 2020·13 cites·14 claims
- 0289US8865653B2Method of treatment for immunogenic treatment resistant cancerROUSSY INST GUSTAVE·Filed 2013·Granted Oct 21, 2014·7 cites·7 claims
- 0388US7378249B2Treatment of cancer using TLR3 agonistsROUSSY INST GUSTAVE·Filed 2005·Granted May 27, 2008·11 cites·12 claims
- 0486US11083774B2Immune checkpoint inhibitor combinationsLYTIX BIOPHARMA AS·Filed 2015·Granted Aug 10, 2021·3 cites·13 claims
- 0586US8409813B2Treatment of cancer using TLR3 agonistsANDRE FABRICE·Filed 2010·Granted Apr 2, 2013·8 cites·13 claims
- 0684US12239686B2Immune checkpoint inhibitor combinationsLYTIX BIOPHARMA AS·Filed 2024·Granted Mar 4, 2025·0 cites·14 claims
- 0783US8129340B2Inhibitors of protein phosphatase 1, GADD34 and protein phosphatase 1/GADD34 complex, preparation and uses thereofKROEMER GUIDO·Filed 2007·Granted Mar 6, 2012·3 cites·10 claims
- 0881US11684640B2Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-basedROUSSY INST GUSTAVE·Filed 2017·Granted Jun 27, 2023·3 cites·4 claims
- 0980US10646521B2Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatmentROUSSY INST GUSTAVE·Filed 2014·Granted May 12, 2020·3 cites·20 claims
- 1077US7625573B2Sensitization process for antigen-presenting cells and means for implementing the processCENTRE NAT RECH SCIENT·Filed 2003·Granted Dec 1, 2009·12 cites·12 claims
- 1177US6685911B1Sensitization process for antigen-presenting cells and means for implementing the processINST NAT SANTE RECH MED·Filed 1999·Granted Feb 3, 2004·43 cites·5 claims
- 1274US8828944B2Compounds and uses thereof to induce an immunogenic cancer cell death in a subjectZITVOGEL LAURENCE·Filed 2011·Granted Sep 9, 2014·3 cites·2 claims
- 1374US8557517B2Toll like receptor 4 dysfunction and the biological applications thereofAPETOH LIONEL·Filed 2007·Granted Oct 15, 2013·4 cites·30 claims
- 1472US12144839B2Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatmentROUSSY INST GUSTAVE·Filed 2023·Granted Nov 19, 2024·0 cites·4 claims
- 1571US9593376B2Natural killer p30 (NKp30) dysfunction and the biological applications thereofZITVOGEL LAURENCE·Filed 2009·Granted Mar 14, 2017·7 cites·6 claims
- 1669US8263344B2Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatmentKROEMER GUIDO·Filed 2007·Granted Sep 11, 2012·5 cites·6 claims
- 1769US2023201305A9Immune checkpoint inhibitor combinationsLYTIX BIOPHARMA AS·Filed 2021·Application pending·0 cites
- 1869US2025332217A1Immune checkpoint inhibitor combinationsLYTIX BIOPHARMA AS·Filed 2025·Application pending·0 cites
- 1967US6849452B1Methods for activating natural killer (NK) cells and means for carrying out said methodsROUSSY INST GUSTAVE·Filed 1999·Granted Feb 1, 2005·31 cites·15 claims
- 2067US2008253998A1Treatment of cancer using tlr3 agonistsROUSSY INST GUSTAVE·Filed 2008·Application pending·0 cites
- 2159US11344586B2Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatmentROUSSY INST GUSTAVE·Filed 2020·Granted May 31, 2022·0 cites·5 claims
- 2256US2011229411A1Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatmentROUSSY INST GUSTAVE·Filed 2008·Application pending·0 cites
- 2355US2025264457A1A biomarker and compositions to increase the therapeutic index of neoadjuvant immunotherapy in muscle-invasive urothelial carcinomaROUSSY INST GUSTAVE·Filed 2023·Application pending·0 cites
- 2455US2024398876A1Biological marker of intestinal dysbiosis, useful for predicting the response of a cancer patient to an anti-pdi drugROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 2554US2008317811A1Treatment of Cancer Using Tlr3 AgonistsROUSSY INST GUSTAVE·Filed 2005·Application pending·0 cites
- 2654US2024288449A1Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapyROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 2753US2020376052A1Combination of oncolytic virus with immune checkpoint modulatorsROUSSY INST GUSTAVE·Filed 2020·Application pending·0 cites
- 2850US12102672B2Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancerROUSSY INST GUSTAVE·Filed 2018·Granted Oct 1, 2024·0 cites·18 claims
- 2947US9557333B2Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum levelROUSSY INST GUSTAVE·Filed 2013·Granted Jan 31, 2017·0 cites·5 claims
- 3044US12246044B2Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the sameROUSSY INST GUSTAVE·Filed 2018·Granted Mar 11, 2025·0 cites·3 claims
- 3141US2022056532A1Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2ROUSSY INST GUSTAVE·Filed 2019·Application pending·0 cites
- 3238US9810692B2Methods for predicting the sensitivity of a subject to immunotherapyROUSSY INST GUSTAVE·Filed 2013·Granted Nov 7, 2017·0 cites·12 claims
- 3336US2019331682A1Methods and kits for predicting the sensitivity of a subject to immunotherapyROUSSY INST GUSTAVE·Filed 2017·Application pending·0 cites
- 3433US2019282632A1Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blockerROUSSY INST GUSTAVE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laurence Zitvogel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →